Home LiteratureArticle Details
PMID: 18575829 Published · ppublish English Journal Article Review

Extracellular ATP and cancer: an overview with special reference to P2 purinergic receptors.

Pathology oncology research : POR ·Vol. 14 ·No. 3 ·2008-09-00 ·Pages 219-31

Deli T, Csernoch L

Abstract

Purinergic signal transduction mechanisms have been appreciated as a complex intercellular signalling network that plays an important regulatory role in both short- and long-term processes in practically every living cell. One of the most intriguing aspects of the field is the participation of ATP and other purine nucleotides in the determination of cell fate and the way they direct cells towards proliferation, differentiation or apoptosis, thereby possibly taking part in promoting or preventing malignant transformation. In this review, following a very brief introduction to the historical aspects of purinergic signalling and a concise overview of the structure of and signal transduction pathways coupled to P2 purinergic receptors, the current theories concerning the possible ways how extracellular ATP can alter the function of tumour cells and the effectiveness of anticancer therapies are discussed, including pharmacological, nutritional, vasoactive and 'anti-antioxidant' actions of the nucleotide. The effects of ATP on animals inoculated with human tumours and on patients with cancer are looked over next, and then an overview of the literature regarding the expression and presumed functions of P2 purinoceptors on tumour cells in vitro is presented, sorted out according to the relevant special clinical fields. The article is closed by reviewing the latest developments in the diagnostic use of P2 purinergic receptors as tumour markers and prognostic factors, while discussing some of the difficulties and pitfalls of the therapeutic use of ATP analogues.

MeSH Terms
Adenosine Triphosphate/analogs & derivatives,pharmacology,therapeutic use Animals Biomarkers, Tumor/metabolism Cell Line, Tumor Disease Models, Animal Humans Neoplasms/diagnosis,drug therapy,metabolism Prognosis Receptors, Purinergic P2/metabolism Signal Transduction/drug effects
Chemicals
Biomarkers, Tumor Receptors, Purinergic P2 Adenosine Triphosphate
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Deli Tamás
Department of Physiology, Research Centre for Molecular Medicine, Medical and Health Science Centre, University of Debrecen, Debrecen, Hungary.
Csernoch László
References (95)
95 references, click to expand
  1. Experimental cancer therapy in mice by adenine nucleotides.
    Eur J Cancer Clin Oncol. 1988 Sep;24(9):1491-7 PMID: 3181271
  2. A glance at adenosine receptors: novel target for antitumor therapy.
    Pharmacol Ther. 2003 Oct;100(1):31-48 PMID: 14550503
  3. Anticancer activities of adenine nucleotides in mice are mediated through expansion of erythrocyte ATP pools.
    Proc Natl Acad Sci U S A. 1989 Mar;86(5):1662-6 PMID: 2922403
  4. Permeation of both cations and anions through a single class of ATP-activated ion channels in developing chick skeletal muscle.
    J Gen Physiol. 1990 Apr;95(4):569-90 PMID: 1692581
  5. Growth inhibition of human tumor cells in soft-agar cultures by treatment with low levels of adenosine 5'-triphosphate.
    Cancer Res. 1983 Sep;43(9):4402-6 PMID: 6871873
  6. P2X7 receptor-dependent blebbing and the activation of Rho-effector kinases, caspases, and IL-1 beta release.
    J Immunol. 2003 Jun 1;170(11):5728-38 PMID: 12759456
  7. Effects of ATP infusion on glucose turnover and gluconeogenesis in patients with advanced non-small-cell lung cancer.
    Clin Sci (Lond). 2000 Jun;98(6):689-95 PMID: 10814606
  8. Extracellular nucleotides and nucleosides induce proliferation and increase nucleoside transport in human glioma cell lines.
    J Neurooncol. 2003 Sep;64(3):211-8 PMID: 14558596
  9. Characterization of calcium-mobilizing, purinergic P2Y(2) receptors in human ovarian cancer cells.
    Mol Hum Reprod. 2000 May;6(5):435-42 PMID: 10775647
  10. Rottlerin inhibits P2X(7) receptor-stimulated phospholipase D activity in chronic lymphocytic leukaemia B-lymphocytes.
    Immunol Cell Biol. 2007 Jan;85(1):68-72 PMID: 17130901
  11. ADP-evoked phospholipase C stimulation and adenylyl cyclase inhibition in glioma C6 cells occur through two distinct nucleotide receptors, P2Y(1) and P2Y(12).
    FEBS Lett. 2002 Feb 27;513(2-3):179-83 PMID: 11904146
  12. ATP- and UTP-activated P2Y receptors differently regulate proliferation of human lung epithelial tumor cells.
    Am J Physiol Lung Cell Mol Physiol. 2003 Aug;285(2):L376-85 PMID: 12691958
  13. Activation of APE1/Ref-1 is dependent on reactive oxygen species generated after purinergic receptor stimulation by ATP.
    Nucleic Acids Res. 2005 Aug 02;33(14):4379-94 PMID: 16077024
  14. Pharmacology and electrophysiology of ATP-activated ion channels.
    Trends Pharmacol Sci. 1992 Mar;13(3):87-90 PMID: 1374198
  15. Expression of the apoptotic calcium channel P2X7 in the glandular epithelium.
    J Mol Histol. 2005 Mar;36(3):159-65 PMID: 15900405
  16. Demonstration of P2Y4 purinergic receptors in the HT-29 human colon cancer cell line.
    Auton Autacoid Pharmacol. 2005 Oct;25(4):163-6 PMID: 16176447
  17. Mitochondrial localization of P2Y1, P2Y2 and P2Y12 receptors in rat astrocytes and glioma C6 cells.
    Brain Res Bull. 2007 Mar 30;71(6):587-92 PMID: 17292801
  18. Disordered purinergic signaling inhibits pathological angiogenesis in cd39/Entpd1-null mice.
    Am J Pathol. 2007 Oct;171(4):1395-404 PMID: 17823293
  19. Purinergic signalling.
    Br J Pharmacol. 2006 Jan;147 Suppl 1:S172-81 PMID: 16402102
  20. The liberation of adenosine triphosphate on antidromic stimulation of sensory nerves.
    J Physiol. 1959 Mar 12;145(3):494-504 PMID: 13642316
  21. The P2X7 receptor sustains the growth of human neuroblastoma cells through a substance P-dependent mechanism.
    Cancer Res. 2006 Jan 15;66(2):907-14 PMID: 16424024
  22. Characterization of calcium-independent purinergic receptor-mediated apoptosis in hormone-refractory prostate cancer.
    BJU Int. 2008 Feb;101(3):352-9 PMID: 18005209
  23. Endogenously expressed truncated P2X7 receptor lacking the C-terminus is preferentially upregulated in epithelial cancer cells and fails to mediate ligand-induced pore formation and apoptosis.
    Nucleosides Nucleotides Nucleic Acids. 2006;25(9-11):1271-6 PMID: 17065105
  24. Expression and responsiveness of P2Y2 receptors in human endometrial cancer cell lines.
    J Clin Endocrinol Metab. 1999 Nov;84(11):4085-91 PMID: 10566654
  25. Oxidative metabolism in cancer growth.
    Curr Opin Clin Nutr Metab Care. 2006 Jul;9(4):339-45 PMID: 16778561
  26. Expression of functional P2-purinergic receptors in primary cultures of human colorectal carcinoma cells.
    Biochem Biophys Res Commun. 1998 Oct 29;251(3):811-7 PMID: 9790992
  27. Immunocytochemical and pharmacological characterisation of P2-purinoceptor-mediated cell growth and death in PC-3 hormone refractory prostate cancer cells.
    Anticancer Res. 2004 Sep-Oct;24(5A):2853-9 PMID: 15517888
  28. Elimination of Ehrlich tumours by ATP-induced growth inhibition, glutathione depletion and X-rays.
    Nat Med. 1995 Jan;1(1):84-8 PMID: 7584960
  29. The effect of a hyposmotic shock and purinergic agonists on K+(Rb+) efflux from cultured human breast cancer cells.
    Biochim Biophys Acta. 2005 Jun 15;1712(1):52-61 PMID: 15890311
  30. Growth inhibitory effect and apoptosis induced by extracellular ATP and adenosine on human gastric carcinoma cells: involvement of intracellular uptake of adenosine.
    Acta Pharmacol Sin. 2006 Aug;27(8):1085-92 PMID: 16867263
  31. Expression and functional characterization of P2Y1 and P2Y12 nucleotide receptors in long-term serum-deprived glioma C6 cells.
    FEBS J. 2007 Apr;274(8):1970-82 PMID: 17355284
  32. Extracellular nucleotides stimulate proliferation in MCF-7 breast cancer cells via P2-purinoceptors.
    Br J Cancer. 1997;75(1):34-9 PMID: 9000595
  33. Extracellular nucleotides inhibit growth of human oesophageal cancer cells via P2Y(2)-receptors.
    Br J Cancer. 2002 Feb 12;86(4):636-44 PMID: 11870549
  34. Receptors for purines and pyrimidines.
    Pharmacol Rev. 1998 Sep;50(3):413-92 PMID: 9755289
  35. Selective enhancement of intratumoural blood flow in malignant gliomas: experimental study in rats by intracarotid administration of adenosine or adenosine triphosphate.
    Acta Neurochir (Wien). 1989;101(1-2):66-74 PMID: 2603771
  36. Cytotoxic effect of extracellular ATP on L1210 leukemic cells and normal hemopoietic stem cells.
    Leuk Res. 1994 Aug;18(8):637-41 PMID: 8065165
  37. Adenosine triphosphate activates mitogen-activated protein kinase in pre-neoplastic and neoplastic ovarian surface epithelial cells.
    Biol Reprod. 2003 Jan;68(1):309-15 PMID: 12493727
  38. Extracellular ATP induces apoptotic signaling in human monocyte leukemic cells, HL-60 and F-36P.
    Arch Pharm Res. 2006 Nov;29(11):1032-41 PMID: 17146973
  39. Early prostate cancer detected using expression of non-functional cytolytic P2X7 receptors.
    Histopathology. 2004 Mar;44(3):206-15 PMID: 14987223
  40. Differentiation-dependent alterations in the extracellular ATP-evoked calcium fluxes of cultured skeletal muscle cells from mice.
    Pflugers Arch. 2007 Jan;453(4):509-18 PMID: 17021795
  41. Purinergic receptor-mediated effects of ATP in high-grade bladder cancer.
    BJU Int. 2008 Jan;101(1):106-12 PMID: 17941929
  42. Glutathione and the rate of cellular proliferation determine tumour cell sensitivity to tumour necrosis factor in vivo.
    Biochem J. 1997 Jul 1;325 ( Pt 1):183-9 PMID: 9224645
  43. Functional genomics of calcium channels in human melanoma cells.
    Int J Cancer. 2007 Jul 1;121(1):55-65 PMID: 17330843
  44. Regulated release of nucleotides and UDP sugars from astrocytoma cells.
    Novartis Found Symp. 2006;276:73-84; discussion 84-90, 107-12, 275-81 PMID: 16805424
  45. Purinergic signalling--an overview.
    Novartis Found Symp. 2006;276:26-48; discussion 48-57, 275-81 PMID: 16805422
  46. Dexamethasone inhibits proliferation and stimulates ecto-5'-nucleotidase/CD73 activity in C6 rat glioma cell line.
    J Neurooncol. 2007 Aug;84(1):1-8 PMID: 17453149
  47. Effects of extracellular nucleotides and nucleosides on prostate carcinoma cells.
    Br J Pharmacol. 2001 Jan;132(2):536-46 PMID: 11159704
  48. Extracellular ATP triggers IL-1 beta release by activating the purinergic P2Z receptor of human macrophages.
    J Immunol. 1997 Aug 1;159(3):1451-8 PMID: 9233643
  49. Activation of Src/kinase/phospholipase C/mitogen-activated protein kinase and induction of neurite expression by ATP, independent of nerve growth factor.
    Neuroscience. 2006 Aug 11;141(1):179-89 PMID: 16730415
  50. Molecular physiology of P2X receptors.
    Physiol Rev. 2002 Oct;82(4):1013-67 PMID: 12270951
  51. P2X7 receptor expression in evolutive and indolent forms of chronic B lymphocytic leukemia.
    Blood. 2002 Jan 15;99(2):706-8 PMID: 11781259
  52. The P2X7 receptor: a novel biomarker of uterine epithelial cancers.
    Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1906-13 PMID: 17035398
  53. Expression of P2Y2 purinoceptors in MCG 101 murine sarcoma cells, and HT-29 human colon carcinoma cells.
    Auton Neurosci. 2004 May 31;112(1-2):69-79 PMID: 15233932
  54. Increased P2X7 receptor expression and function in thyroid papillary cancer: a new potential marker of the disease?
    Endocrinology. 2008 Jan;149(1):389-96 PMID: 17947359
  55. Role of the purinergic P2Z receptor in spontaneous cell death in J774 macrophage cultures.
    Biochem Biophys Res Commun. 1996 Jan 5;218(1):176-81 PMID: 8573127
  56. Adenosine triphosphate infusion increases liver energy status in advanced lung cancer patients: an in vivo 31P magnetic resonance spectroscopy study.
    Hepatology. 2002 Feb;35(2):421-4 PMID: 11826418
  57. Treatment of human tumor cells with ADP or ATP yields arrest of growth in the S phase of the cell cycle.
    J Cell Physiol. 1983 Mar;114(3):279-83 PMID: 6833403
  58. Randomized clinical trial of adenosine 5'-triphosphate on tumor growth and survival in advanced lung cancer patients.
    Anticancer Drugs. 2003 Sep;14(8):639-44 PMID: 14501386
  59. Atypical PKCzeta is involved in RhoA-dependent mitogenic signaling by the P2Y(12) receptor in C6 cells.
    FEBS J. 2006 Apr;273(8):1843-54 PMID: 16623718
  60. Randomized clinical trial of adenosine 5'-triphosphate in patients with advanced non-small-cell lung cancer.
    J Natl Cancer Inst. 2000 Feb 16;92(4):321-8 PMID: 10675381
  61. Mechanisms of caspase-1 activation by P2X7 receptor-mediated K+ release.
    Am J Physiol Cell Physiol. 2004 May;286(5):C1100-8 PMID: 15075209
  62. The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart.
    J Physiol. 1929 Nov 25;68(3):213-37 PMID: 16994064
  63. Generation of extracellular ATP in blood and its mediated inhibition of host weight loss in tumor-bearing mice.
    Biochem Pharmacol. 1989 Dec 1;38(23):4261-6 PMID: 2597198
  64. Calcium mobilization and cell proliferation activated by extracellular ATP in human ovarian tumour cells.
    Cell Calcium. 1993 Mar;14(3):209-18 PMID: 8500137
  65. Proteomic and functional evidence for a P2X7 receptor signalling complex.
    EMBO J. 2001 Nov 15;20(22):6347-58 PMID: 11707406
  66. P2X7 receptor-mediated apoptosis of human cervical epithelial cells.
    Am J Physiol Cell Physiol. 2004 Nov;287(5):C1349-58 PMID: 15269006
  67. Upregulation of CD39/NTPDases and P2 receptors in human pancreatic disease.
    Am J Physiol Gastrointest Liver Physiol. 2007 Jan;292(1):G223-30 PMID: 16920697
  68. Extracellular ATP-dependent suppression of proliferation and induction of differentiation of human HL-60 leukemia cells by distinct mechanisms.
    Biochem Pharmacol. 2000 Dec 1;60(11):1585-91 PMID: 11077040
  69. Phase II study of intravenous adenosine 5'-triphosphate in patients with previously untreated stage IIIB and stage IV non-small cell lung cancer.
    Invest New Drugs. 1998;16(1):81-5 PMID: 9740548
  70. P2Y2- and P2Y4 purinergic receptors are over-expressed in human colon cancer.
    Auton Autacoid Pharmacol. 2007 Apr;27(2):79-84 PMID: 17391276
  71. Effect of extracellular ATP on the growth of hormone-refractory prostate cancer in vivo.
    BJU Int. 2008 Jul;102(1):108-12 PMID: 18325054
  72. The metabotropic P2Y4 receptor participates in the commitment to differentiation and cell death of human neuroblastoma SH-SY5Y cells.
    Neurobiol Dis. 2005 Feb;18(1):100-9 PMID: 15649700
  73. Expression of P2X7 in human hematopoietic cell lines and leukemia patients.
    Leuk Res. 2004 Dec;28(12):1313-22 PMID: 15475073
  74. Purinergic nerves.
    Pharmacol Rev. 1972 Sep;24(3):509-81 PMID: 4404211
  75. Nucleotide receptors stimulation by extracellular ATP controls Hsp90 expression through APE1/Ref-1 in thyroid cancer cells: a novel tumorigenic pathway.
    J Cell Physiol. 2006 Oct;209(1):44-55 PMID: 16741950
  76. Effect of extracellular ATP on breast tumor cell growth, implication of intracellular calcium.
    Cancer Lett. 1994 Sep 30;85(1):47-54 PMID: 7923101
  77. Effect of extracellular ATP on the human leukaemic cell line K562 and its multidrug counterpart.
    Mol Cell Biochem. 2006 Sep;289(1-2):111-24 PMID: 16823516
  78. Adenosine triphosphate (ATP) enhances the antitumor effect of etoposide (VP16) in lung cancer cells.
    Oncol Rep. 2004 Nov;12(5):1139-42 PMID: 15492806
  79. Contribution from P2X and P2Y purinoreceptors to ATP-evoked changes in intracellular calcium concentration on cultured myotubes.
    Pflugers Arch. 2007 Jan;453(4):519-29 PMID: 17043813
  80. P2X and P2Y purinergic receptors on human intestinal epithelial carcinoma cells: effects of extracellular nucleotides on apoptosis and cell proliferation.
    Am J Physiol Gastrointest Liver Physiol. 2005 May;288(5):G1024-35 PMID: 15662049
  81. Human melanomas express functional P2 X(7) receptors.
    Cell Tissue Res. 2005 Sep;321(3):411-8 PMID: 15991050
  82. A loss-of-function polymorphic mutation in the cytolytic P2X7 receptor gene and chronic lymphocytic leukaemia: a molecular study.
    Lancet. 2002 Mar 30;359(9312):1114-9 PMID: 11943260
  83. Pathophysiology and therapeutic potential of purinergic signaling.
    Pharmacol Rev. 2006 Mar;58(1):58-86 PMID: 16507883
  84. P2Y purinergic receptors regulate the growth of human melanomas.
    Cancer Lett. 2005 Jun 16;224(1):81-91 PMID: 15911103
  85. The role of phosphometabolites in cell proliferation, energy metabolism, and tumor therapy.
    J Bioenerg Biomembr. 1997 Aug;29(4):315-30 PMID: 9387092
  86. Pharmacological characterization of the human P2Y13 receptor.
    Mol Pharmacol. 2003 Jul;64(1):104-12 PMID: 12815166
  87. Biophysics of P2X receptors.
    Pflugers Arch. 2006 Aug;452(5):501-12 PMID: 16708237
  88. Is there a basis for distinguishing two types of P2-purinoceptor?
    Gen Pharmacol. 1985;16(5):433-40 PMID: 2996968
  89. Expression of purinergic receptors in non-melanoma skin cancers and their functional roles in A431 cells.
    J Invest Dermatol. 2003 Aug;121(2):315-27 PMID: 12880424
  90. Phase I trial of extracellular adenosine 5'-triphosphate in patients with advanced cancer.
    Med Pediatr Oncol. 1996 Sep;27(3):165-73 PMID: 8699994
  91. Water induces autocrine stimulation of tumor cell killing through ATP release and P2 receptor binding.
    Cell Death Differ. 2004 Dec;11 Suppl 2:S172-80 PMID: 15459753
  92. Extracellular ATP induces cytokine expression and apoptosis through P2X7 receptor in murine mast cells.
    J Immunol. 2005 Apr 1;174(7):3880-90 PMID: 15778342
  93. Identification of the platelet ADP receptor targeted by antithrombotic drugs.
    Nature. 2001 Jan 11;409(6817):202-7 PMID: 11196645
  94. Differentiation between cancerous and normal hyperplastic lobules in breast lesions.
    Breast Cancer Res Treat. 2004 Jan;83(1):1-10 PMID: 14997049
  95. ERK1/2 and p38 pathways are required for P2Y receptor-mediated prostate cancer invasion.
    Cancer Lett. 2004 Nov 25;215(2):239-47 PMID: 15488643
Article Info
Journal
Pathology oncology research : POR
Abbr.
Pathol Oncol Res
ISSN
1219-4956
DOI
10.1007/s12253-008-9071-7
Published
2008-09-00
Epub
2008-00-25
Pages
219-31
Language
English
Region
Switzerland
NLM ID
9706087
Subset
IM
External Links
PubMed source DOI: 10.1007/s12253-008-9071-7 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2